Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Bobak R. Azamian Sells 4,856 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) CEO Bobak R. Azamian sold 4,856 shares of the stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $15.45, for a total value of $75,025.20. Following the sale, the chief executive officer now owns 1,111,106 shares in the company, valued at approximately $17,166,587.70. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Tarsus Pharmaceuticals Trading Up 1.4 %

Shares of TARS traded up $0.22 during mid-day trading on Wednesday, reaching $15.73. 94,152 shares of the company’s stock traded hands, compared to its average volume of 111,910. Tarsus Pharmaceuticals, Inc. has a 12 month low of $10.80 and a 12 month high of $21.47. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.40 and a quick ratio of 16.40. The stock has a market cap of $419.55 million, a P/E ratio of -5.76 and a beta of 0.67. The stock’s 50-day moving average is $15.42 and its two-hundred day moving average is $16.06.

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) last announced its quarterly earnings data on Wednesday, November 9th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.14. Tarsus Pharmaceuticals had a negative return on equity of 34.24% and a negative net margin of 324.99%. Research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Trading of Tarsus Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Deerfield Management Company L.P. Series C bought a new stake in Tarsus Pharmaceuticals during the 2nd quarter valued at about $19,334,000. TimesSquare Capital Management LLC increased its position in shares of Tarsus Pharmaceuticals by 124.6% during the second quarter. TimesSquare Capital Management LLC now owns 1,481,710 shares of the company’s stock worth $21,633,000 after acquiring an additional 822,110 shares during the period. Frazier Life Sciences Management L.P. increased its position in shares of Tarsus Pharmaceuticals by 26.1% during the second quarter. Frazier Life Sciences Management L.P. now owns 1,787,527 shares of the company’s stock worth $26,098,000 after acquiring an additional 370,370 shares during the period. Assenagon Asset Management S.A. bought a new stake in shares of Tarsus Pharmaceuticals during the second quarter valued at approximately $5,281,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Tarsus Pharmaceuticals by 42.7% in the third quarter. Vanguard Group Inc. now owns 935,649 shares of the company’s stock valued at $16,018,000 after purchasing an additional 279,826 shares during the period. 76.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Oppenheimer lowered their target price on shares of Tarsus Pharmaceuticals from $66.00 to $43.00 in a report on Thursday, November 10th.

About Tarsus Pharmaceuticals

(Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.